Erythromycin Enteric-coated Tablets

This product belongs to the macrolide antibiotics. It is antibacterial to Staphylococcus (except methicillin-resistant strains), all groups of streptococci and Gram-positive bacilli. Neisseria, Haemophilus influenzae, Bordetella pertussis, etc. are also sensitive to this product. This product also has antibacterial effects on various anaerobic bacteria except Bacteroides fragilis and Fusobacterium. It also has inhibitory effects on Legionella, Campylobacter fetus, some spirochetes, Mycoplasma pneumoniae, Rickettsia and Chlamydia. This product is an antibacterial agent, but it also has a bactericidal effect on some bacteria at high concentrations. It can penetrate the bacterial cell membrane and reversibly bind to the 50S subunit of the bacterial ribosome near the donor site (P site), blocking the transfer RNA (t-RNA) from binding to the P site, and also blocking the displacement of the polypeptide chain from the acceptor site (A site) to the P site, thereby inhibiting bacterial protein synthesis.

The main ingredient of this product is erythromycin.

This product is enteric-coated tablets or enteric-coated film-coated tablets. After removing the coating, it appears white or off-white.

This product can be used as an alternative medicine for the treatment of the following infections in patients allergic to penicillin: acute tonsillitis, acute pharyngitis, sinusitis caused by hemolytic streptococci, pneumococcus, etc.; scarlet fever and cellulitis caused by hemolytic streptococci; diphtheria and diphtheria carriers; gas gangrene, anthrax, tetanus; actinomycosis; syphilis; listeriosis, etc. It can also be used to treat Legionnaires' disease, Mycoplasma pneumonia, Chlamydia pneumoniae pneumonia, urogenital infections caused by Chlamydia, Mycoplasma, Chlamydia trachomatis conjunctivitis, Neisseria gonorrhoeae infection, oral infections caused by anaerobic bacteria, Campylobacter jejuni enteritis, and whooping cough.

Oral administration: 1-2g per day for adults, divided into 3-4 doses. Patients with Legionnaires' disease, 2-4g per day, divided into 4 doses. Children, 30-50mg/kg per day, divided into 3-4 doses.

1. Gastrointestinal reactions include diarrhea, nausea, vomiting, upper abdominal pain, pain in the mouth and tongue, decreased appetite, etc., and the incidence is related to the dose. 2. Hepatotoxicity is rare. Patients may experience fatigue, nausea, vomiting, abdominal pain, fever, abnormal liver function, and occasionally jaundice. 3. When used in large doses (ge; 4g/day), especially in patients with liver and kidney diseases or elderly patients, hearing loss may occur, which is mainly related to excessive blood drug concentration (12mg/L). Most of them can be recovered after drug withdrawal. 4. Allergic reactions are manifested as drug fever, rash, eosinophilia, etc., with an incidence of about 0.5% to 1%. 5. Others, occasionally arrhythmia, oral or vaginal candidiasis.

Patients who are allergic to this product or other macrolide drugs are contraindicated.

Precautions for children: Not yet clear. Precautions for pregnancy and lactation: This product can enter the fetal circulation through the placental barrier, so pregnant women should use it with caution. A considerable amount of this product enters breast milk, so lactating women should use it with caution or stop breastfeeding. Precautions for the elderly: Not yet clear.

1. This product can inhibit the metabolism of anti-epileptic drugs such as carbamazepine and valproic acid, resulting in increased blood concentrations and toxic reactions. Combination with fentanyl can inhibit the metabolism of the latter and prolong its duration of action. Combination with antihistamines such as astemizole or terfenadine can increase cardiac toxicity, and combination with cyclosporine can increase the latter's blood concentration and produce nephrotoxicity; 2. It has an antagonistic effect on chloramphenicol and lincomycin, and it is not recommended to use them at the same time; 3. This product is an antibacterial agent and can interfere with the bactericidal efficacy of penicillin. Therefore, when a rapid bactericidal effect is required, such as the treatment of meningitis, the two should not be used at the same time; 4. Patients who take warfarin for a long time may prolong the prothrombin time when using this product, thereby increasing the risk of bleeding. Elderly patients should pay special attention. When both must be used at the same time, the dose of warfarin should be appropriately adjusted, and the prothrombin time should be closely observed; 5. Except for dihydroxypropylphylline, the simultaneous use of xanthine drugs can reduce the hepatic clearance of aminophylline, resulting in an increase in serum aminophylline concentration and (or) increased toxic reactions. This phenomenon is more likely to occur after 6 days of combined use, and the reduction in aminophylline clearance is proportional to the peak blood concentration of this product. Therefore, during and after the combined treatment of the two, the dose of xanthine drugs should be adjusted; 6. Combination with other hepatotoxic drugs may enhance hepatotoxicity; 7. High doses of this product combined with ototoxic drugs, especially in patients with renal impairment, may increase ototoxicity; 8. When used in combination with lovastatin, its metabolism can be inhibited and blood concentration can be increased, which may cause rhabdomyolysis; when used in combination with midazolam or triazolam, the clearance of the two can be reduced and their effects can be enhanced; 9. This product can obstruct the enterohepatic circulation of sex hormones, and combined with oral contraceptives can reduce their efficacy.

Sealed, store in a dry place.

0.125 g

36 months.

China National Medicines Guorui Pharmaceutical Co., Ltd.

• Founded in:

  1998-08-05

• Address:

  No. 16, Chaoyang East Road, Economic and Technological Development Zone, Huainan City, Anhui Province

• Tax NO.:

  9134040072334670XN

• Registered Funds:

  483.0167 million yuan

• Email:

  Log in to view